DPP-4 therapy cuts weight gain and hypoglycaemia

Treating type-2 diabetes with dipeptidyl peptidase-4 (DPP-4) inhibitors reduces patients' risk of weight gain and hypoglycaemia, data presented at the American Diabetes Association meeting suggest.

Weight gain: reduced by DPP-4s (Photograph: Jason Heath Lancy)
Weight gain: reduced by DPP-4s (Photograph: Jason Heath Lancy)

A study of 858 patients with type-2 diabetes found that adding the DPP-4 inhibitor saxagliptin to metformin achieved similar reductions in HbA1c levels to the treatment with the sulphonylurea glipizide and metformin.

However, fewer patients given saxagliptin experienced side effects such as weight gain during the one-year study period.

A separate study of 1,172 patients with type-2 diabetes compared the DPP-4 inhibitor sitagliptin with the sulphonylurea glipizide.

The researchers found that patients given sitagliptin were five times more likely to achieve a composite outcome encompassing HbA1c reduction of 0.5 percentage points, lack of hypoglycaemia and absence of weight gain.

Patients treated with sitagliptin experienced a weight reduction compared with those given glipizide.

The study presented last week was a post hoc analysis of data from a trial in patients with inadequate glycaemic control on metformin monotherapy.

Results of a study of the as-yet-unlicensed drug linagliptin, also a DPP-4 inhibitor, showed that it was also not associated with weight gain or an increased risk of hypoglycaemia.

The research also showed that linagliptin has a primarily non-renal route of excretion, which is a novel pharmaceutical feature for a DPP-4 inhibitor. The drug acted similarly in patients with mild and moderate renal impairment and patients with normal renal function.

DPP-4 inhibitors have been shown to increase levels of the incretin hormones glucagon-like peptide 1 and gastric inhibitory peptide, leading to improvements in a body's ability to lower blood glucose levels.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Deadline missed for PHE report on how ethnicity affects COVID-19 outcomes

Deadline missed for PHE report on how ethnicity affects COVID-19 outcomes

Public Health England (PHE) has missed its 31 May deadline for reporting on how factors...

Lockdown complacency threatens second COVID-19 spike that could 'overwhelm' NHS

Lockdown complacency threatens second COVID-19 spike that could 'overwhelm' NHS

Complacency around easing coronavirus lockdown measures could trigger a second wave...

Practices asked to 'proactively address' unmet health needs during pandemic

Practices asked to 'proactively address' unmet health needs during pandemic

GP practices in England have been told to assess where care has been delayed during...

Hertfordshire GP trainee Dr Abdorreza Sedghi dies from COVID-19

Hertfordshire GP trainee Dr Abdorreza Sedghi dies from COVID-19

A GP trainee working in Hertfordshire who has been praised for his ‘charisma and...

GP anger as shielding advice changed 'without warning'

GP anger as shielding advice changed 'without warning'

GPs have hit out at a lack of warning over changes to advice for patients on shielding...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...